The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development

Shougeng Liu; Sihong Chen; Chengfang Tang; Yingxi Zhao; Wei Cui; Lina Jia; Lihui Wang

doi:10.3389/fonc.2022.970833

The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development

Front Oncol. 2022 Sep 26:12:970833. doi: 10.3389/fonc.2022.970833. eCollection 2022.

Authors

Shougeng Liu^{1

2}, Sihong Chen^{1

2}, Chengfang Tang^{1

2}, Yingxi Zhao^{1

2}, Wei Cui¹, Lina Jia^{1

2}, Lihui Wang^{1

2}

Affiliations

¹ Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
² Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Shenyang, China.

Abstract

As a reversible and dynamic epigenetic modification, N6-methyladenosine (m6A) modification is ubiquitous in eukaryotic cells. m6A methylation is prevalent in almost all RNA metabolism processes that affect the fate of cells, including cancer development. As indicated by the available evidence, targeting m6A regulators may play a crucial role in tumor therapy and multidrug resistance. Currently, many questions remain uncovered. Here, we review recent studies on m6A modification in various aspects of tumor progression, tumor immunity, multidrug resistance, and therapeutic targets to provide new insight into the m6A methylation process.

Keywords: RNA epigenetics; cancer; cancer immunity; clinical perspectives; m6A modification.

Publication types

Review